Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calsym Plus is a multi-ingredient nutritional supplement developed and marketed by Symbiosis Labs, an Indian pharmaceutical company. It is formulated as a combination of calcium carbonate, cholecalciferol (vitamin D3), magnesium, and zinc, primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies, as well as for supporting bone health in conditions like osteoporosis and osteomalacia. Calcium carbonate serves as a source of elemental calcium, which is essential for maintaining bone density and structural integrity. Cholecalciferol acts as an agonist at the vitamin D receptor (VDR), facilitating the intestinal absorption of calcium and maintaining systemic calcium and phosphate homeostasis. Magnesium and zinc are included as essential minerals that serve as enzymatic cofactors in bone mineralization and metabolic processes. Calsym Plus is typically administered orally in tablet form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol + magnesium + zinc.